Liver Transplantation Unit, Hospital Dr. Cosme Argerich, Buenos Aires, Argentina.
HPB (Oxford). 2007;9(6):435-9. doi: 10.1080/13651820701769701.
Resection of colorectal liver metastases has become a standard of care, although the value of this procedure in non-colorectal non-neuroendocrine (NCRNNE) metastases remains controversial and is still a matter of debate. The aim of the study was to determine the utility of liver resection in the long-term outcome of patients with NCRNNE metastases.
The records of 106 patients who underwent liver resection for NCRNNE metastases in the period 1989 to 2006 at 5 HPB Centers in Argentina were analyzed. Patient demographics, tumor characteristics, type of resection, long-term outcome and prognostic factors were analyzed. Depending on primary tumor sites, a comparative analysis of survival was performed.
Mean age was 54 (17-76). Hepatic metastases were solitary in 62.3% and unilateral in 85.6%. Primary tumor sites: Urogenital (37.7%), sarcomas (21.7%), breast (17.9%), gastrointestinal (6.6%), melanoma (5.7%), and others (10.4%). Fifty-one major hepatectomies and 55 minor resections were performed. Twenty patients underwent synchronous resections. An R0 resection could be achieved in 89.6%. Perioperative mortality was 1.8%. Overall, 1-year, 3-year, and 5-year survival rates were 67%, 34%, and 19%, respectively. Survival was significantly longer for metastases of urogenital (p=0.0001) and breast (p=0.003) origin. Curative resections (p=0.04) and metachronous disease (p=0.0001) were predictors of better survival.
Liver resection is an effective treatment for NCRNNE liver metastases; it gives satisfactory long-term survival especially in metachronous disease, in patients with metastases from urogenital and breast tumors and when R0 procedures can be performed.
结直肠肝转移的切除术已成为一种标准治疗方法,尽管该手术在非结直肠神经内分泌(NCRNNE)转移中的价值仍存在争议,并且仍然存在争议。本研究旨在确定肝切除术在 NCRNNE 转移患者长期预后中的作用。
分析了 1989 年至 2006 年期间在阿根廷的 5 个 HPB 中心接受 NCRNNE 转移肝切除术的 106 名患者的记录。分析了患者的人口统计学特征、肿瘤特征、切除术类型、长期结果和预后因素。根据原发肿瘤部位,进行了生存比较分析。
平均年龄为 54 岁(17-76 岁)。肝转移灶单发者占 62.3%,单侧者占 85.6%。原发肿瘤部位:泌尿生殖系统(37.7%)、肉瘤(21.7%)、乳腺(17.9%)、胃肠道(6.6%)、黑色素瘤(5.7%)和其他(10.4%)。51 例进行了大肝切除术,55 例进行了小切除术。20 例患者进行了同步切除术。89.6%可实现 R0 切除术。围手术期死亡率为 1.8%。总的来说,1 年、3 年和 5 年生存率分别为 67%、34%和 19%。泌尿生殖系统(p=0.0001)和乳腺(p=0.003)来源的转移的生存时间明显更长。根治性切除术(p=0.04)和异时性疾病(p=0.0001)是更好生存的预测因素。
肝切除术是治疗 NCRNNE 肝转移的有效方法;它能提供令人满意的长期生存,特别是在异时性疾病、泌尿生殖系统和乳腺肿瘤转移以及可以进行 R0 手术的患者中。